Head to Head Analysis: Appili Therapeutics (OTCMKTS:APLIF) and Sigilon Therapeutics (NASDAQ:SGTX)

Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) and Appili Therapeutics (OTCMKTS:APLIF – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

52.2% of Sigilon Therapeutics shares are owned by institutional investors. 6.5% of Sigilon Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Appili Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sigilon Therapeutics and Appili Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sigilon Therapeutics	0	0	1	0	3.00
Appili Therapeutics	0	0	0	0	N/A

Sigilon Therapeutics presently has a consensus target price of $0.00, indicating a potential downside of 100.00%.

Risk & Volatility

Sigilon Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Appili Therapeutics has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500.

Profitability

This table compares Sigilon Therapeutics and Appili Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigilon Therapeutics	-253.33%	-87.94%	-40.53%
Appili Therapeutics	N/A	N/A	-178.76%

Earnings and Valuation

This table compares Sigilon Therapeutics and Appili Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigilon Therapeutics	$12.94 million	18.23	-$43.56 million	($1.15)	-6.30
Appili Therapeutics	$1.11 million	3.58	-$20.04 million	($0.11)	-0.30

Appili Therapeutics has lower revenue, but higher earnings than Sigilon Therapeutics. Sigilon Therapeutics is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Sigilon Therapeutics

(Get Rating)

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Appili Therapeutics

(Get Rating)

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.